Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report released on Monday, AnalystRatings.com reports. They currently have a $84.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 24.94% from the company’s previous close.
Several other brokerages also recently weighed in on CRSP. BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 13th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 16th. Oppenheimer increased their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Finally, Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $71.38.
Shares of CRSP stock opened at $67.23 on Monday. The firm has a fifty day simple moving average of $63.51 and a 200-day simple moving average of $50.09. The company has a market capitalization of $3.76 billion, a PE ratio of -19.54 and a beta of 3.30. Crispr Therapeutics has a twelve month low of $24.56 and a twelve month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Equities research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $465,000. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last three months. Insiders own 21.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of CRSP. Nikko Asset Management Americas Inc. raised its position in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after acquiring an additional 906,006 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Crispr Therapeutics in the third quarter worth $21,167,000. Price T Rowe Associates Inc. MD increased its stake in Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN increased its stake in Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in Crispr Therapeutics during the second quarter valued at $5,165,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.